NCT01588236 - Effect of KYG0395 on Primary Dysmenorrhea | Biotech Hunter

Enrollment

280

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Primary Dysmenorrhea

Interventions

DRUG

high dose KYG0395

3 KYG0395 capsules tid (morning, midday, and evening)

DRUG

lower dose KYG0395

3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)

DRUG

Placebo

3 capsules of placebo tid (morning, midday, and evening)

Trial Locations (23)

11777

Suffolk OB-GYN, Port Jefferson

15206

Clinical Trials Research Services, Pittsburgh

27103

Lynhurst Clinical Research, Winston-Salem

29201

SC Clinical Research Center, LLC, Columbia

30342

Atlanta Women's Research Institute, Inc., Atlanta

37215

Dial Research Associates, Inc., Nashville

43213

Columbus Center for Women's Health Research, Columbus

48106

ClinSite, Ann Arbor

59808

Montana Medical Research, Missoula

60634

Chicago Research Center, Inc., Chicago

72205

Lynn Institute of the Ozarks, Little Rock

77030

Advances in Health, Houston

78229

Clinical Trials of Texas, Inc., San Antonio

78414

Advanced Research Associates, Corpus Christi

78705

Benchmark Research, Austin

83404

Women's Healthcare Associates dba Rosemark WomenCare Specialists, Idaho Falls

85015

Women's Health Research, Phoenix

92123

Women's Health Care at Frost Street, San Diego

98105

Women's Clinical Research Center, Seattle

06320

Coastal Connecticut Research, New London

02720

Genesis Clinical Research, Fall River

08648

Lawrence OB GYN Associates, Lawrenceville

08536

The Center for Women's Health and Wellness LLC, Plainsboro